{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:40:39Z","timestamp":1788349239883,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.euroneuro.2015.12.002","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T03:41:13Z","timestamp":1450323673000},"page":"331-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Efficacy of Silexan in mixed anxiety\u2013depression \u2013 A randomized, placebo-controlled trial"],"prefix":"10.1016","volume":"26","author":[{"given":"Siegfried","family":"Kasper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Volz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Dienel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Schl\u00e4fke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2015.12.002_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2009.03.012","article-title":"The serotonin-1A receptor in anxiety disorders","volume":"66","author":"Akimova","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib2","series-title":"DSM","first-page":"5","article-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1037\/a0015813","article-title":"Universal-based prevention of syndromal and subsyndromal social anxiety: a randomized controlled study","volume":"77","author":"Aune","year":"2009","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib4","article-title":"Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging","volume":"18","author":"Baldinger","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900025815","article-title":"Defining response and remission in anxiety disorders: toward an integrated approach","volume":"11","author":"Bandelow","year":"2006","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Psychiatry Clin. Pr."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0165-0327(02)00343-9","article-title":"Mixed anxiety-depression in a 1 year follow-up study: shift to other diagnoses or remission?","volume":"79","author":"Barkow","year":"2004","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/15622975.2013.804195","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders","volume":"14","author":"Bauer","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2307\/2533441","article-title":"Evaluation of experiments with adaptive interim analyses","volume":"50","author":"Bauer","year":"1994","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.12.002_bib10","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/00004850-200008002-00007","article-title":"Selective serotonin reuptake inhibitors in mixed anxiety\u2013depression","volume":"15","author":"Berk","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jad.2013.11.011","article-title":"Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: results from the EURODEP concerted action","volume":"155","author":"Braam","year":"2014","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib12","first-page":"31","article-title":"Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): a review and analysis","volume":"16","author":"Breggin","year":"20032004","journal-title":"Int. J. Risk Saf. Med."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0165-0327(99)00138-X","article-title":"Sertraline in the treatment of mixed anxiety and depression disorder","volume":"59","author":"Carrasco","year":"2000","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1037\/0021-843X.100.3.316","article-title":"Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications","volume":"100","author":"Clark","year":"1991","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0447.2004.00301.x","article-title":"Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies","volume":"109","author":"Cuijpers","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4088\/PCC.v10n0209","article-title":"Treating depression and anxiety in primary care","volume":"10","author":"Culpepper","year":"2008","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1192\/bjp.bp.107.036707","article-title":"Public health significance of mixed anxiety and depression: beyond current classification","volume":"192","author":"Das-Munshi","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib18","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.291.21.2581","article-title":"Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys","volume":"291","author":"Demyttenaere","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/dmd.112.050203","article-title":"Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers","volume":"41","author":"Doroshyenko","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib20","first-page":"175","article-title":"Ten ways to improve the treatment of depression and anxiety in adults","volume":"10","author":"Dunlop","year":"2013","journal-title":"Ment. Health Fam. Med."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/PCC.v03n0105","article-title":"SSRI antidepressant medications: adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/da.20231","article-title":"A three-year follow-up of major depression, dysthymia, minor depression and subsyndromal depression: results from a population-based study","volume":"24","author":"Forsell","year":"2007","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-244X-14-128","article-title":"The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review","volume":"14","author":"Haller","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib24","series-title":"ECDEU Assessment Manual for Psychopharmacology.","first-page":"193","article-title":"Hamilton anxiety scale (HAMA)","author":"Hamilton","year":"1976"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40268-014-0065-5","article-title":"No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol\/levonorgestrel combination","volume":"14","author":"Heger-Mahn","year":"2014","journal-title":"Drugs RD"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.12.002_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/13651501.2013.813555","article-title":"An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review","volume":"17","author":"Kasper","year":"2013","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib27","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.euroneuro.2015.07.024","article-title":"Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep \u2013 a randomized, placebo-controlled trial","volume":"25","author":"Kasper","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib28","doi-asserted-by":"crossref","first-page":"V01","DOI":"10.1055\/s-0033-1338176","article-title":"Silexan (WS\u00ae 1265) vermindert begleitende depressive Symptome bei Patienten mit Angsterkrankungen","volume":"34","author":"Kasper","year":"2013","journal-title":"Z. Phytother."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1017\/S1461145714000017","article-title":"Lavender oil preparation Silexan is effective in generalized anxiety disorder \u2013 a randomized, double-blind comparison to placebo and paroxetine","volume":"17","author":"Kasper","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/YIC.0b013e32833b3242","article-title":"Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of \u05f3subsyndromal\u05f3 anxiety disorder: a randomized, double-blind, placebo controlled trial","volume":"25","author":"Kasper","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archpsyc.1992.01820090044008","article-title":"Major depression and generalized anxiety disorder. Same genes, (partly) different environments?","volume":"49","author":"Kendler","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1017\/S0033291705004538","article-title":"Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication","volume":"35","author":"Kessler","year":"2005","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1521-4036(199906)41:3<261::AID-BIMJ261>3.0.CO;2-U","article-title":"Inference on multiple endpoints in clinical trials with adaptive interim analyses","volume":"41","author":"Kieser","year":"1999","journal-title":"Biom. J."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S0033291703001466","article-title":"The prevalence and co-morbidity of subthreshold psychiatric conditions","volume":"34","author":"Lewinsohn","year":"2004","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib35","article-title":"Multiple comparisons in drug clinical trials and pre-clinical assays: a priori ordered hypotheses","volume":"3\u201318","author":"Maurer","year":"1995"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib36","first-page":"16","article-title":"Efficacy of an eight week trial of imipramine and citalopram in patients with mixed anxiety\u2013depressive disorder","volume":"3","author":"Moin","year":"2008","journal-title":"Iran. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0924-977X(94)90093-0","article-title":"Clinically relevant effect sizes in depression","volume":"4","author":"Montgomery","year":"1994","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuint.2011.05.002","article-title":"Stress, glucocorticoids and glutamate release: effects of antidepressant drugs","volume":"59","author":"Musazzi","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib40","series-title":"EDCEU Assessment in Psychopharmacology. U.S","first-page":"217","article-title":"12-CGI. clinical global impressions","author":"National Institute of Mental Health","year":"1970"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00004714-200104000-00004","article-title":"Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis","volume":"21","author":"Rausch","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1176\/appi.ajp.2012.12070999","article-title":"DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses","volume":"170","author":"Regier","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF02599221","article-title":"Subsyndromal (\"mixed\") anxiety--depression in primary care","volume":"9","author":"Roy-Byrne","year":"1994","journal-title":"J. Gen. Int. Med."},{"issue":"Suppl. 30","key":"10.1016\/j.euroneuro.2015.12.002_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1192\/S0007125000298395","article-title":"Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care","volume":"168","author":"Sartorius","year":"1996","journal-title":"Br. J. Psychiatry."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1037\/a0026517","article-title":"Human anterior and posterior hippocampus respond distinctly to state and trait anxiety","volume":"12","author":"Satpute","year":"2012","journal-title":"Emotion"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","article-title":"5-HT(1A) receptor function in major depressive disorder","volume":"88","author":"Savitz","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib47","doi-asserted-by":"crossref","first-page":"e59998","DOI":"10.1371\/journal.pone.0059998","article-title":"Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels","volume":"8","author":"Schuwald","year":"2013","journal-title":"Plos One"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.12.002_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib49","series-title":"Manual for the State-Trait Anxiety Inventory","author":"Spielberger","year":"1983"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jad.2009.06.008","article-title":"Who is MADD? Mixed anxiety depressive disorder in the general population","volume":"121","author":"Spijker","year":"2010","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.euroneuro.2015.12.002_bib51","first-page":"20","article-title":"Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link","volume":"58","author":"Stahl","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0165-0327(95)00002-5","article-title":"Mixed anxiety\u2013depression in a primary-care clinic","volume":"34","author":"Stein","year":"1995","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1192\/bjp.179.3.191","article-title":"The case for cothymia: mixed anxiety and depression as a single diagnosis","volume":"179","author":"Tyrer","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.phymed.2012.02.020","article-title":"Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder","volume":"19","author":"Uehleke","year":"2012","journal-title":"Phytomedicine"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib55","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1192\/bjp.bp.110.085092","article-title":"Mixed anxiety and depressive disorder outcomes: prospective cohort study in primary care","volume":"198","author":"Walters","year":"2011","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00004850-200015060-00002","article-title":"Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey","volume":"15","author":"Wittchen","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.12.002_bib58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phymed.2009.10.006","article-title":"A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder","volume":"17","author":"Woelk","year":"2010","journal-title":"Phytomedicine"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib59","series-title":"International Statistical Classification of Diseases and Related Health Porblems, Tenth Revision (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib60","series-title":"Diagnostic and Management Guidelines for Mental Disorders in Primary Care","author":"World Health Organization","year":"1996"},{"key":"10.1016\/j.euroneuro.2015.12.002_bib61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15003855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15003855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T12:29:34Z","timestamp":1567427374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0924977X15003855"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.12.002","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Silexan in mixed anxiety\u2013depression \u2013 A randomized, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}